Response Options to Blood Volume Monitoring in Fluid Overloaded Hemodialysis Patients (BVM-Reg)
|ClinicalTrials.gov Identifier: NCT01416753|
Recruitment Status : Completed
First Posted : August 15, 2011
Last Update Posted : September 3, 2012
Background: Data generated with the body composition monitor (BCM, Fresenius) show based on bioimpedance technology, that chronic fluid overload in hemodialysis patients is associated with poor survival. However, removing excess fluid by lowering dry weight can be accompanied by intradialytic and postdialytic complications. Here, we aim at testing the hypothesis that, in comparison to conventional hemodialysis, blood-volume monitored regulation of ultrafiltration and dialysate conductivity (UCR) and/or regulation of ultrafiltration and temperature (UTR) will decrease complications when ultrafiltration volumes are systematically increased in fluid overloaded hemodialysis patients.
Methods/Design: BCM-measurements yield results on fluid overload (in liters), relative to extracellular water (ECW). In this prospective, multicenter, triple-arm, parallel group, cross-over, randomized, controlled clinical trial, we use BCM-measurements, routinely introduced in our 3 maintenance hemodialysis centers shortly prior to the start of the study, to recruit 60 hemodialysis patients with fluid overload (defined as ≥15% ECW). Patients are randomized 1:1:1 into UCR, UTR and conventional hemodialysis groups. BCM-determined, 'final' dry weight is set as -7% ECW postdialysis, and reached by reducing the previous dry weight, in steps of 0.1 kg per 10 kg body weight, during 12 hemodialysis sessions (one study phase). In case of intradialytic complications, dry weight reduction is decreased, according to a pre-specified algorithm. A comparison of intra- and postdialytic complications among study groups constitutes the primary endpoint. In addition, we will assess relative weight reduction, changes in residual renal function, quality of life measures, and predialysis levels of various laboratory parameters including C-reactive protein, troponin T, and N-terminal pro-B-type natriuretic peptide, before and after the first study phase (secondary outcome parameters).
Discussion: Patients are not requested to revert to their initial degree of fluid overload after each study phase, Therefore, the cross-over design of the present study merely serves the purpose of secondary end-point evaluation, for example to determine patient choice of treatment modality. Previous studies on blood volume monitoring have yielded inconsistent results. Since we include only patients with BCM-determined fluid overload, we expect a benefit for all study participants, due to strict fluid management which decreases the mortality risk of hemodialysis patients.
|Condition or disease||Intervention/treatment||Phase|
|Overhydration Dry Weight Reduction||Device: UCR Device: UTR||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||64 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Controlled Clinical Trial Comparing, in Fluid-Overloaded Hemodialysis Patients, Three Strategies of Fluid Removal: Regulation of Ultrafiltration and Dialysate Conductivity, Regulation of Ultrafiltration and Temperature, and Standard Hemodialysis|
|Study Start Date :||September 2011|
|Actual Primary Completion Date :||August 2012|
|Actual Study Completion Date :||August 2012|
Active Comparator: UCR
regulation of ultrafiltration and conductivity
BVM-based regulation of ultrafiltration and conductivity
Active Comparator: UTR
regulation of ultrafiltration and temperature
BVM-based regulation of ultrafiltration; regulation of temperature
No Intervention: conventional dialysis
dry weight reduction without BVM
- The primary outcome measure is the number of intradialytic complications in each of the three study groups, only during the first study phase. [ Time Frame: 4 weeks for one study phase ]The study sample will consist of 60 patients with ECV ≥15%, by BCM-measurement. For the primary endpoint analysis, we will assess the differences in intradialytic complications between the three study groups, only during the first study phase. The UCR and UTR groups will be tested against the conventional HD control group, and afterwards against one another.
- (see detailed description listed above, under primary objectives) [ Time Frame: (as above) ](as above)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01416753
|Medical University of Vienna|
|Vienna, Austria, 1090|
|Principal Investigator:||Marcus D Säemann, MD||Medical University of Vienna, Austria, 1090 Vienna|